2m 2m 2m 2m 2m 2m 2m
JANUX THERAPEUTS (JANX)
NASDAQ
$14.65-$0.26 (-1.76%)
Price as of Jun 23, 2026 6:37 PM EDT- $874.5MMarket Cap
- -37.33%1-Year Change
- BiotechnologyIndustry
JANUX THERAPEUTS (JANX)
$14.65-$0.26 (-1.76%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 10.0M -5.55% | 10.6M +30.99% | 8.1M -6.14% | 8.6M +136.79% | |
Cost of Revenue | 167.7M +53.21% | 109.4M +35.00% | 81.1M +7.08% | 75.7M +107.03% | |
Gross Profit | -157.7M +59.51% | -98.8M +35.45% | -73.0M +8.78% | -67.1M +103.74% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -125.9M +84.09% | -68.4M +24.52% | -54.9M +2.77% | -53.4M +103.69% | |
Depreciation and Amortization Expense | 2.0M -1.50% | 2.1M +5.37% | 2.0M +132.46% | 841,000 +644.25% | |
Total Operating Expenses | 209.4M +39.18% | 150.5M +40.37% | 107.2M +9.43% | 98.0M +108.90% | |
Operating Profit | -157.7M +59.51% | -98.8M +35.45% | -73.0M +8.78% | -67.1M +103.74% | |
Interest Income | 44.0M +47.53% | 29.9M +103.28% | 14.7M +264.24% | 4.0M +1,468.87% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 44.0M +47.53% | 29.9M +103.28% | 14.7M +264.24% | 4.0M +1,468.87% | |
Total Nonoperating Income and Expense | 44.0M +47.53% | 29.9M +103.28% | 14.7M +264.24% | 4.0M +1,468.87% | |
Income before Taxes | -157.7M +59.51% | -98.8M +35.45% | -73.0M +8.78% | -67.1M +103.74% | |
Income Taxes | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -113.6M +64.69% | -69.0M +18.36% | -58.3M -7.56% | -63.1M +93.01% | |
Net Income from Continuing Operations Applicable to Common | -113.6M +64.69% | -69.0M +18.36% | -58.3M -7.56% | -63.1M +93.01% | |
Basic EPS and Net Income | -1.83 +42.97% | -1.28 -3.03% | -1.32 -13.16% | -1.52 +9.35% | |
Diluted EPS and Net Income | -1.83 +42.97% | -1.28 -3.03% | -1.32 -13.16% | -1.52 +9.35% | |
Basic Weighted Average Shares | 62.0M +15.28% | 53.8M +22.12% | 44.0M +6.14% | 41.5M +76.24% | |
Diluted Weighted Average Shares | 62.0M +15.28% | 53.8M +22.12% | 44.0M +6.14% | 41.5M +76.24% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 52.3M -87.85% | 430.6M +2,142.15% | 19.2M -62.66% | 51.4M +44.53% | |
Short-Term Investments | 914.2M +53.76% | 594.6M +83.04% | 324.8M +17.86% | 275.6M -18.80% | |
Cash and Cash Equivalents and Short-Term Investments | 966.6M -5.72% | 1.0B +197.99% | 344.0M +5.20% | 327.0M -12.79% | |
Total Current Assets | 975.9M -5.59% | 1.0B +195.97% | 349.2M +5.05% | 332.4M -11.82% | |
Accumulated Depreciation | 7.0M +40.69% | 5.0M +69.94% | 2.9M +199.79% | 972,000 +641.98% | |
Property and Plant and Equipment and Net | 3.9M -20.81% | 4.9M -30.54% | 7.0M -1.17% | 7.1M +401.84% | |
Total Long-Term Assets | 2.6M -9.57% | 2.9M +14.95% | 2.5M +80.50% | 1.4M +254.59% | |
Total Assets | 1.0B -5.65% | 1.1B +179.05% | 380.4M +4.50% | 364.0M -4.16% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 25.0M +43.18% | 17.5M +33.96% | 13.0M -21.05% | 16.5M +28.99% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 19.7M -7.19% | 21.3M -7.60% | 23.0M -13.97% | 26.8M +3,723.29% | |
Total Liabilities | 44.7M +15.51% | 38.7M +7.42% | 36.1M -16.67% | 43.3M +220.59% | |
Retained Earnings | -351.4M +47.79% | -237.8M +40.88% | -168.8M +52.77% | -110.5M +133.00% | |
Total Stockholders Equity | 956.8M -6.45% | 1.0B +197.02% | 344.3M +7.36% | 320.7M -12.44% | |
Total Shares Outstanding | 60.4M +2.23% | 59.1M +27.70% | 46.3M +11.14% | 41.6M +0.90% | |
Cash Flow | |||||
Cash from Operating Activities | -82.2M +87.69% | -43.8M -13.37% | -50.6M +17.83% | -42.9M +152.84% | |
Capital Expenditures | 1.0M +190.53% | 359,000 -80.59% | 1.9M -71.30% | 6.4M +334.89% | |
Cash from Investing Activities | -301.0M +16.65% | -258.0M +526.36% | -41.2M -170.70% | 58.3M +117.09% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 4.9M -99.31% | 713.2M +1,097.75% | 59.5M +11,809.60% | 500,000 -99.87% | |
Financials Ratio | |||||
Gross Margin | -1,576.67% +68.89% | -933.58% +3.40% | -902.87% +15.90% | -779.04% N/A | |
Operating Margin | -1,576.67% +68.89% | -933.58% +3.40% | -902.87% +15.90% | -779.04% N/A | |
Return on Assets | -11.02% +15.10% | -9.57% -38.90% | -15.66% -7.63% | -16.96% N/A | |
Return on Equity | -11.48% +13.73% | -10.09% -42.42% | -17.53% -4.50% | -18.36% N/A | |
Revenue Growth | -5.55% -117.92% | 30.99% +604.53% | -6.14% -104.49% | 136.79% N/A | |
Current Ratio | 39.04 -34.06% | 59.21 +120.94% | 26.80 +33.06% | 20.14 N/A | |
Cash Ratio | 2.09 -91.51% | 24.66 +1,573.71% | 1.47 -52.70% | 3.12 N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow